• Medicare’s GLP‑1 Bridge starts July 1, 2026, giving eligible beneficiaries access to Eli Lilly weight‑loss drugs Zepbound and Foundayo for a $50 monthly copay.
  • EU CHMP recommended Eli Lilly's Jaypirca (pirtobrutinib) for CLL across lines after Phase 3 showed efficacy and tolerability; European Commission decision expected in one to two months.